Anzeige
Mehr »
Donnerstag, 12.02.2026 - Börsentäglich über 12.000 News
Drohnen, Robotik, E-Autos: Diese Hightech-Aktie könnte jetzt zünden
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
103 Leser
Artikel bewerten:
(0)

Global $6.1 Billion Virus Filtration Market to 2025

DUBLIN, October 25, 2017 /PRNewswire/ --

The "Virus Filtration Market Analysis by Product (Consumables, Instruments), by Technology (Filtration, Chromatography), by Application (Biologicals, Medical Devices), by End-use and Segment Forecasts, 2014 - 2025" report has been added to Research and Markets' offering.

Research and Markets Logo

The global virus filtration market is expected to reach USD 6.1 billion by 2025

The market is expected to witness a CAGR of 12.5% over the forecast period, increasing demand for biological products such as vaccines, therapeutic proteins, blood & blood products, cellular & gene therapy, tissue, and stem cell products is a major factor driving market growth.

Biopharmaceuticals are mainly derived from human, animal, and plants and therefore require a scrutinized virus filtration procedure to avoid virus contamination in the production. Therefore, the necessity of this procedure during the production of biologics is expected to boost the market growth.

Many leading biopharmaceuticals and biotechnology manufacturers are involved in R&D to develop innovative biological products. For instance, in 2016, Pfizer Inc. invested USD 7,872.0 million in R&D, which was around 8% more than the R&D investment in 2015.

This investment was mainly undertaken to boost innovation and productivity in R&D to accomplish a sustainable pipeline of vaccines and differentiated therapies with lucrative commercial opportunities. Virus filtration is an important step in biologics development, thus, the increasing R&D on biologics is expected to drive the demand for these products.

Further key findings from the report suggest:



  • The consumables segment was the largest revenue generating segment of the market in 2016 owing to the increased usage of consumables including reagents, kits, and membranes in biologics downstream processing
  • In the technology segment, the chromatography segment is projected to grow at the highest growth rate during the forecast period. This is because of product advancements such as disposable or single-use membranes that eliminate the risk of a potential virus contaminant
  • The biologicals segment accounted for the largest share of the market and is projected to maintain its dominance during the forecast period due to rising prevalence of chronic diseases such as cancer, blood disorders, and diabetes
  • The biopharmaceutical & biotechnology companies segment is projected to grow at the highest CAGR during the forecast period because of increasing investment in R&D and production of biologics
  • North America dominated the overall market in 2016 primarily due to the presence of several leading biotechnology companies and increased R&D activities for the development of biologics
  • The Asia Pacific market is estimated to grow at the highest CAGR during the forecast period. Growing presence of CROs in Asia Pacific countries including China and India due to the presence of a large genome pool, less stringent regulations, and availability of economical labor force is contributing to the growth of this region.
  • Some of the major players are Merck KGaA; Sartorius; Danaher; Thermo Fisher Scientific, Inc.; Charles River Laboratories International, Inc.; GE Healthcare; Asahi Kasei Medical Co., Ltd.; WuXi PharmaTech (Cayman) Inc.; Lonza; and Clean Cells

Key Topics Covered:

Chapter 1 Research Methodology

Chapter 2 Executive Summary
2.1 Market Snapshot

Chapter 3 Virus Filtration Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.2 Market Driver Analysis
3.2.1 Rising demand for biologics
3.2.2 Increasing R&D investment
3.2.3 Compliance with regulatory framework
3.3 Market Restraint Analysis
3.3.1 Intense competition among vendors
3.4 Market Opportunity Analysis
3.4.1 Growth in pharmaceutical outsourcing industry
3.4.2 Rising adoption of single-use technologies
3.5 Market Challenge Analysis
3.5.1 Complexity of biologics
3.6 Key Opportunities Prioritized
3.7 Virus Filtration - SWOT Analysis, By Factor (political & legal, economic and technological)
3.8 Industry Analysis - Porter's
3.9 Virus Filtration Market: Market Position Analysis

Chapter 4 Virus Filtration Market: Product Estimates & Trend Analysis
4.1 Virus Filtration Market: Product Movement Analysis
4.2 Consumables
4.2.2 Reagents and kits
4.2.3 Others
4.3 Instruments
4.3.2 Filtration systems
4.3.3 Chromatography systems
4.4 Services

Chapter 5 Virus Filtration Market: Technology Estimates & Trend Analysis
5.1 Virus Filtration Market: Technology Movement Analysis
5.2 Filtration
5.3 Chromatography

Chapter 6 Virus Filtration Market: Application Estimates & Trend Analysis
6.1 Virus Filtration Market: Application Movement Analysis
6.2 Biologicals
6.2.2 Vaccines and therapeutics
6.2.3 Blood and blood products
6.2.4 Cellular and gene therapy products
6.2.5 Tissue and tissue products
6.2.6 Stem cell products
6.3 Medical devices
6.4 Water purification
6.5 Air purification

Chapter 7 Virus Filtration Market: End Use Estimates & Trend Analysis
7.1 Virus Filtration Market: End Use Movement Analysis
7.2 Biopharmaceutical & Biotechnology Companies
7.3 Contract Research Organizations
7.4 Medical Devices Companies
7.5 Academic Institutes & Research Laboratories

Chapter 8 Virus Filtration Market: Regional Estimates & Trend Analysis, by Product, Application, End Use

Chapter 9 Competitive Landscape

  • Merck KGaA
  • Danaher
  • Sartorius AG
  • Thermo Fisher Scientific Inc.
  • GE Healthcare
  • Charles River Laboratories International, Inc.
  • Asahi Kasei Medical Co., Ltd.
  • WuXi PharmaTech Inc.
  • Lonza Group Ltd.
  • Clean Cells Inc.

For more information about this report visit https://www.researchandmarkets.com/research/ff8pvm/virus_filtration

Media Contact:


Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716



© 2017 PR Newswire
Favoritenwechsel
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.